
Jesús Sierra
Articles
-
1 month ago |
europeanurology.com | Juan Rivas |Jesús Sierra
Emmett L, Subramaniam S, Crumbaker M, et alLancet Oncol 2024;25:563–71Experts’ summary:The ENZA-p trial assessed the efficacy and safety of combining [177Lu]Lu-PSMA-617 with enzalutamide in comparison to enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) and at least two risk factors for early progression. This open-label, randomized, phase 2 trial enrolled 162 patients across 15 centers in Australia.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →